These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18221305)

  • 1. Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.
    Hamed MR; Tarr AW; McClure CP; Ball JK; Hickling TP; Irving WL
    J Viral Hepat; 2008 May; 15(5):339-45. PubMed ID: 18221305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
    Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
    J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.
    Baumert TF; Wellnitz S; Aono S; Satoi J; Herion D; Tilman Gerlach J; Pape GR; Lau JY; Hoofnagle JH; Blum HE; Liang TJ
    Hepatology; 2000 Sep; 32(3):610-7. PubMed ID: 10960457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
    Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
    J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
    Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
    J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
    Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
    Shaw ML; McLauchlan J; Mills PR; Patel AH; McCruden EA
    J Med Virol; 2003 Jul; 70(3):361-72. PubMed ID: 12766998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon.
    Hattori M; Yoshioka K; Aiyama T; Iwata K; Terazawa Y; Ishigami M; Yano M; Kakumu S
    Hepatology; 1998 Jun; 27(6):1703-10. PubMed ID: 9620346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
    Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV antibody quantitative levels in liver transplant patients: do they have any relevance in clinical practice?
    Jain A; Menegus M; Mohanka R; Orloff M; Abt P; Mantry P; Bozorgzadeh A
    Exp Clin Transplant; 2006 Jun; 4(1):475-80. PubMed ID: 16827647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response.
    Moreno M; Pérez-Alvarez R; Rodrigo L; Pérez-López R; Suárez-Leiva P
    J Viral Hepat; 2006 Jan; 13(1):28-33. PubMed ID: 16364079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to use virological tools for optimal management of chronic hepatitis C.
    Chevaliez S; Pawlotsky JM
    Liver Int; 2009 Jan; 29 Suppl 1():9-14. PubMed ID: 19207960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic relevance of F protein in chronic hepatitis C virus infection.
    Komurian-Pradel F; Rajoharison A; Berland JL; Khouri V; Perret M; Van Roosmalen M; Pol S; Negro F; Paranhos-Baccalà G
    Hepatology; 2004 Oct; 40(4):900-9. PubMed ID: 15382175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC).
    Nattermann J; Schneiders AM; Leifeld L; Langhans B; Schulz M; Inchauspé G; Matz B; Brackmann HH; Houghton M; Sauerbruch T; Spengler U
    J Hepatol; 2005 Apr; 42(4):499-504. PubMed ID: 15763336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis C virus.
    Nakano I; Fukuda Y; Katano Y; Hayakawa T
    J Infect Dis; 1999 Oct; 180(4):1328-33. PubMed ID: 10479166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.
    Mancini N; Canducci F; Carletti S; Berardinelli E; Serafini G; Grieco A; Perotti M; Malcangi G; Danieli MG; Varaldo PE; Clementi M; Burioni R
    J Biol Regul Homeost Agents; 2003; 17(2):183-7. PubMed ID: 14518720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.